Skip to main content

Table 1 Baseline characteristics of 65 HIV/HCV-coinfected patients with decompensated cirrhosis categorized according to receipt of anti-HCV treatment during follow-up

From: Prognostic value of liver stiffness in HIV/HCV-Coinfected patients with decompensated cirrhosis

Baseline characteristic Patients who received HCV treatment (n = 17) Patients who did not receive HCV treatment (n = 48) All patients (N = 65)
Male sex - n (%) 13 (76) 30 (62) 43 (66)
Age, years – median (IQR) 46 (42–49) 46 (43–50) 46 (43–50)
HIV acquired by IDU – n (%) 12 (70) 45 (94) 57 (88)
Nadir, cells/mm3 – median (IQR) 199 (76–292) 121 (45–225) 136 (52–242)
CD4+ cells/mm3 – median (IQR) 294 (216–482) 258 (160–423) 293 (165–424)
CDC disease category C (%) 6 (35) 16 (33) 22 (34)
cART (%) 16 (94) 40 (83) 56 (86)
HIV-RNA < 5 0 copies/mL (%) 10 (59) 37 (77) 47 (71)
HBsAg-positive – n (%) 0 (0) 5(10) 5 (8)
Alcohol intake > 50 g/day – n (%) 2 (12) 11 (23) 13 (20)
First decompensation – n (%)
 Ascites 14 (82) 40 (83) 54 (83)
 Variceal bleeding 2 (12) 3 (6) 5 (8)
 Hepatic encephalopathy 0 (0) 5 (10) 5 (8)
 Non-obstructive jaundice 1 (6) 0 (0) 1 (1)
Hepatocellular carcinoma – median (IQR) 1 (6) 2 (4) 3 (4.6)
Esophageal varices – n (%)
 Yes 5 (29) 25 (52) 30 (15)
 No 8 (47) 9 (19) 17 (2)
 Unknown 4 (23) 14 (29) 18 (28)
Child-Pugh score – median (IQR) 7 (5–9) 7 (6–8) 7 (5–8)
MELD score – median (IQR) 11 (7.5–15.5) 11 (7–14) 11 (7–14)
Serum albumin, g/dL – median (IQR) 3.5 (2.4–4.2) 3.0 (2.5–3.7) 3.1 (2.5–3.9)
FIB-4 value – median (IQR) 6.5 (3.1–13.5) 6.4 (4.2–10.6) 6.4 (3.8–10.6)
Liver stiffness, kPa – median (IQR) 50 (34–70) 48 (35–63) 48 (35–64)
LSPS – median (IQR) 8.8 (4.9–17.4) 10.5 (8–16.3) 10.3 (7.6–16.4)
HCV genotype – median (IQR)
 1 12 (70) 26 (54) 38 (58)
 2 0 (0) 1 (2) 1 (1.5)
 3 3 (18) 9 (19) 12 (18.5)
 4 2 (12) 3 (6) 5 (7.7)
 Unknown 0 (0) 9 (19) 9 (13.8)
  1. Abbreviations: HCV hepatitis C virus, IQR interquartile range, HIV human immunodeficiency virus, CDC Centers for Disease Control and Prevention, cART combination antiretroviral therapy, HBsAg hepatitis B surface antigen, LSPS Liver stiffness x spleen diameter-to-platelet ratio